Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7569784 | 0.80 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL7564260 | 0.79 | CRHR1 (0.47) | CRHR1PDE1B | |
| SCHEMBL7561611 | 0.78 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL7569873 | 0.77 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL7569867 | 0.76 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL7562809 | 0.70 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL7562834 | 0.68 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL7591216 | 0.68 | TP53 (0.43) | CRHR1PDE1B | |
| SCHEMBL7562041 | 0.68 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL9054069 | 0.68 | CRHR1 (0.41) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020065290-A1 | Novel deazapurine derivatives: a new class of CRF1 specific ligands | NEUROGEN CORPORATION | 2002-05-30 | — | — | US | claimed |
| EP-0770080-B1 | NOVEL DEAZAPURINE DERIVATIVES; A NEW CLASS OF CRF1 SPECIFIC LIGANDS | NEUROGEN CORP (US) | 1999-07-14 | — | — | EP | claimed |
| US-5644057-A | Deazapurine derivatives; a new class of CRF1 specific ligands | NEUROGEN CORPORATION (US) | 1997-07-01 | — | — | US | claimed |
| WO-1996035689-A1 | NOVEL DEAZAPURINE DERIVATIVES; A NEW CLASS OF CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-11-14 | — | — | WO | claimed |
| US-6495688-B2 | USED AS CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONISTS, IN THERAPY AND DIAGNOSIS OF STRESS RELATED DISORDERS SUCH AS POST TRAUMATIC STRESS DISORDER (PTSD) AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-20020065290-A1 | Novel deazapurine derivatives: a new class of CRF1 specific ligands | NEUROGEN CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-6281220-B1 | PYRROLO(3,2-D)PYRIMIDIN-4-AMINES AND PYRROLO(3,2-B)PYRIDIN-4-AMINES, AND THEIR USE AS ANTAGONISTS OF CORTICOTROPIN-RELEASING FACTOR | NEUROGEN CORPORATION | 2001-08-28 | — | — | US | disclosed |
| US-6020492-A | Deazapurine derivatives; a new class of CRF1 specific ligands | NEUROGEN CORPORATION (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0770080-B1 | NOVEL DEAZAPURINE DERIVATIVES; A NEW CLASS OF CRF1 SPECIFIC LIGANDS | NEUROGEN CORP (US) | 1999-07-14 | — | — | EP | disclosed |
| US-5644057-A | Deazapurine derivatives; a new class of CRF1 specific ligands | NEUROGEN CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996035689-A1 | NOVEL DEAZAPURINE DERIVATIVES; A NEW CLASS OF CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065290-A1 | Novel deazapurine derivatives: a new class of CRF1 specific ligands | CRHR1, CRH, CRHR2 | CRHR1 1/4885PDE1B 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.